LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Shares of Liquidia Corporation LQDA have lost 13.9% in a month against the industry’s growth of 1.5%. The stock has lagged the broader sector and the S&P 500 Index.
The selloff accelerated after LiquidiaLQDA-- reported second-quarter results on Aug. 12. Although earnings and revenues exceeded consensus estimates, the upside was relatively modest, leaving investors unimpressed and weighing on the stock.
The recent pullback has also erased part of the strong gains LQDALQDA-- delivered earlier in 2026. Against this backdrop, investors may want to weigh Liquidia’s key growth drivers against the risks and challenges facing the company to determine whether the stock’s long-term opportunity remains compelling.
LQDA Underperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
LQDA’s Yutrepia Gains Traction
Lead drug Yutrepia is an inhaled dry-powder formulation of treprostinil developed using Liquidia’s proprietary PRINT technology. The technology delivers the drug deeper into the lungs through an easy-to-use inhaler while enabling higher doses than other inhaled treprostinil therapies.
Launched in June 2025, Yutrepia was approved by the FDA in May 2025 for the treatment of both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
As of July 31, 2026, Liquidia had received approximately 5,900 unique prescriptions since launch and started more than 5,000 patients on therapy.
More than 1,100 physicians had prescribed Yutrepia since its launch as of July 31, with more than 30% having written prescriptions for at least five patients. The prescription-to-start conversion rate remained above 85%.
Strong Yutrepia sales helped drive the company's fourth consecutive profitable quarter.
Yutrepia appears to be gaining market share while expanding the inhaled prostacyclin market.
Liquidia currently generates revenues from sales of Yutrepia inhalation powder, and through a profit-sharing arrangement with Sandoz under a promotion agreement originally signed in August 2018 and subsequently amended. The agreement allows Liquidia to share in the profits generated from sales of Sandoz's generic Treprostinil Injection in the United States.
Treprostinil Injection is a fully substitutable generic formulation of treprostinil for parenteral administration in the United States. Liquidia holds exclusive rights to commercialize the product and collaborates with Sandoz on its commercial strategy.
However, Sandoz retains ownership of Treprostinil Injection and holds the associated abbreviated new drug application.
LQDA Works to Expand Yutrepia’s Label
LQDA plans to explore Yutrepia in additional indications, including pulmonary hypertension associated with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF) and Raynaud’s phenomenon associated with systemic sclerosis (SSc-RP).
The FDA recently granted Fast Track designation to Yutrepia inhalation powder for the treatment of SSc-RP.
For Liquidia, the designation enables more frequent interactions with the FDA during development, allows for the potential rolling review of a new drug application, and, if applicable criteria are met, may support eligibility for priority review and/or accelerated approval.
Liquidia plans to initiate RE-WARM, a phase IIa, randomized, open-label, dose-finding study of Yutrepia in approximately 75 adults with SSc experiencing symptomatic Raynaud's phenomenon attacks. RE-WARM is expected to begin in October 2026, with primary completion targeted for February 2027.
Liquidia is also developing L606, an investigational liposomal formulation of treprostinil licensed from Pharmosa Biopharm, designed for twice-daily administration using a short-duration, next-generation nebulizer. It is also being evaluated in PAH and PH-ILD. The phase III Re-Spire study on L606 is currently enrolling.
LQDA’s Overdependence on Yutrepia
While Yutrepia remains the key driver of LQDA’s top-line growth, the company continues to rely heavily on the drug as its primary source of revenue expansion. This dependence creates concentration risk, particularly given Liquidia’s relatively lean pipeline and limited number of near-term growth opportunities beyond Yutrepia.
Adding to the risk profile is Liquidia’s ongoing patent dispute with United Therapeutics UTHR concerning Yutrepia’s use in PH-ILD. Management has stated that an adverse ruling could result in royalty obligations or other injunctive or adjunctive relief. With a decision potentially coming at any time, the litigation represents a headwind that could adversely impact Yutrepia’s economics, market opportunity or commercialization prospects.
LQDA’s Valuation and Estimate Movement
Going by the price/sales ratio, LQDA shares currently trade at 6.10X forward sales, higher than the industry’s average of 1.89X but lower than its mean of 14.67X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share (EPS) has moved south to $2.57 from $3.02, and that for 2027 EPS has declined to $4.38 from $4.92 in the past 60 days.
Image Source: Zacks Investment Research
Avoid LQDA for Now
Liquidia's products and pipeline candidates for PAH compete across several established and clinically validated treatment pathways. UTHR markets four medicines in the United States to treat PAH, namely Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; under an in-license from Eli Lilly and Company) tablets. Remodulin is approved for both subcutaneous and intravenous use.
Insmed INSM is also advancing several clinical-stage programs in respiratory diseases, including TPIP and INS1148. TPIP is an inhaled dry powder formulation of the treprostinil prodrug treprostinil palmitil, which may offer a differentiated product profile for PH-ILD, PAH, PPF and IPF.
Despite Yutrepia’s strong launch and encouraging commercial traction, Liquidia’s investment case remains exposed to several meaningful risks. The company continues to be heavily dependent on Yutrepia for growth, while its relatively lean pipeline provides limited diversification.
Any slowdown in prescription growth, reimbursement challenges or increasing competitive pressure could therefore have a material impact on Liquidia’s revenue trajectory and overall growth prospects.
The ongoing patent litigation with UTHR over Yutrepia’s use in PH-ILD represents another significant overhang. An adverse ruling could restrict commercialization, remove the PH-ILD indication or result in monetary damages, creating substantial uncertainty around Yutrepia’s long-term commercial opportunity.
Meanwhile, competition from established PAH therapies could make it increasingly difficult for Yutrepia to sustain its momentum and capture meaningful market share.
While 2026 and 2027 EPS estimates have declined, rising R&D expenses could further weigh on profitability and limit the potential for meaningful earnings leverage in the near term.
Overall, LQDA’s heavy reliance on Yutrepia, ongoing litigation risk, competitive pressures, elevated valuation and rising costs create an unfavorable risk-reward profile.
Hence, we recommend that both current and prospective investors avoid the stock for now.
LQDA has a Zacks Rank #4 (Sell) at present.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Liquidia Corporation (LQDA): Free Stock Analysis Report
United Therapeutics Corporation (UTHR): Free Stock Analysis Report
Insmed, Inc. (INSM): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners. Copyright 2006-2026 Zacks Equity Research, Inc. editor@zacks.com (Manaing editor) webmaster@zacks.com (Webmaster)
